About this Research Topic
This Research Topic is part of the series of "Hepatocellular Carcinoma: Novel Treatment Strategies":
Hepatocellular Carcinoma: Novel Treatment Strategies - Volume I
Hepatocellular Carcinoma: Novel Treatment Strategies - Volume II
Building on the foundational knowledge established about Tyrosine Kinase Inhibitors (TKIs) in Volumes I and II, Volume III will expand the scope also to Immune Checkpoint Inhibitors (ICIs). We will delve deeper into innovative therapeutic approaches for managing Hepatocellular Carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) against their respective challenges.
HCC not only seriously endangers the physical and mental health of patients, but also poses a significant challenge to public health. The majority of patients diagnosed with advanced HCC are not eligible to receive radical treatment, such as surgery, targeted molecular therapy (i.e. oral protein kinase inhibitors) or precision chemotherapy (i.e. transarterial chemoembolization or the long-acting sustained-release formulation of antitumor agents) is the main therapeutic strategy effective for advanced HCC.
Although molecular targeted drugs, such as Sorafenib, can delay the progression of HCC disease and prolong patient survival, they still present a number of challenges: (1) Sorafenib treatment in advanced HCC patients. There are individual differences in the initial sensitivity of patients to Sorafenib, and most patients who initially respond well to Sorafenib will eventually develop drug tolerance as the treatment progresses; (2) Existing treatment strategies (e.g. Sorafenib treatment requires oral high-dose of [800mg per day]) can cause serious side effects while treating cancer; (3) Recently, Lenvatinib has been approved as a first-line therapy, and Regorafenib as a second-line therapy, with the hope that there may be further reports reviewing their tolerance in the future. (4) HCC-targeted drug therapy remains costly. (5) Some novel agents, including Donafeinib, Regorafenib, Lenvatinib, and Carbozantinib have similar Physiological mechanisms, and share similar chemical structures unit with sorafenib: all these compounds are built based on the skeleton structure of 1-(4-(pyridin-4-yloxy)phenyl)urea.
In this Research Topic, we aim to provide an overview of the recent progress around HCC treatment, especially HCC-ICC-related drug therapy and the molecular mechanism of drug resistance (not only for TKIs, but also for ICIs), encompassing relevant basic and translational studies.
We welcome submission of Original Research, Mini Review and Review articles focusing on the sub-topics below:
• Molecular mechanisms related to the HCC or ICC, i.e. the molecular mechanism of antitumor drug resistance, proliferation or metastasis
• Small molecule kinase inhibitors or chemotherapeutic drugs with new structures for HCC or ICC treatment
• New long-acting and sustained-release anti-tumor drugs on HCC or ICC, including chemotherapy, TKIs and ICIs
• Nanomedicine and materials for HCC or ICC treatment
• Molecular markers based on novel clinical laboratory technology
• HCC, ICC-related metabolic, metabolomics studies
• Progress in intrahepatic cholangiocarcinoma treatment and research
• Clinical application of surgical robots
• HCC, ICC-related organoid studies
Please note: manuscripts submitted consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Hepatocellular Carcinoma: Novel Treatment Strategies - Volume I
Hepatocellular Carcinoma: Novel Treatment Strategies - Volume II
Building on the foundational knowledge established about Tyrosine Kinase Inhibitors (TKIs) in Volumes I and II, Volume III will expand the scope also to Immune Checkpoint Inhibitors (ICIs). We will delve deeper into innovative therapeutic approaches for managing Hepatocellular Carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) against their respective challenges.
HCC not only seriously endangers the physical and mental health of patients, but also poses a significant challenge to public health. The majority of patients diagnosed with advanced HCC are not eligible to receive radical treatment, such as surgery, targeted molecular therapy (i.e. oral protein kinase inhibitors) or precision chemotherapy (i.e. transarterial chemoembolization or the long-acting sustained-release formulation of antitumor agents) is the main therapeutic strategy effective for advanced HCC.
Although molecular targeted drugs, such as Sorafenib, can delay the progression of HCC disease and prolong patient survival, they still present a number of challenges: (1) Sorafenib treatment in advanced HCC patients. There are individual differences in the initial sensitivity of patients to Sorafenib, and most patients who initially respond well to Sorafenib will eventually develop drug tolerance as the treatment progresses; (2) Existing treatment strategies (e.g. Sorafenib treatment requires oral high-dose of [800mg per day]) can cause serious side effects while treating cancer; (3) Recently, Lenvatinib has been approved as a first-line therapy, and Regorafenib as a second-line therapy, with the hope that there may be further reports reviewing their tolerance in the future. (4) HCC-targeted drug therapy remains costly. (5) Some novel agents, including Donafeinib, Regorafenib, Lenvatinib, and Carbozantinib have similar Physiological mechanisms, and share similar chemical structures unit with sorafenib: all these compounds are built based on the skeleton structure of 1-(4-(pyridin-4-yloxy)phenyl)urea.
In this Research Topic, we aim to provide an overview of the recent progress around HCC treatment, especially HCC-ICC-related drug therapy and the molecular mechanism of drug resistance (not only for TKIs, but also for ICIs), encompassing relevant basic and translational studies.
We welcome submission of Original Research, Mini Review and Review articles focusing on the sub-topics below:
• Molecular mechanisms related to the HCC or ICC, i.e. the molecular mechanism of antitumor drug resistance, proliferation or metastasis
• Small molecule kinase inhibitors or chemotherapeutic drugs with new structures for HCC or ICC treatment
• New long-acting and sustained-release anti-tumor drugs on HCC or ICC, including chemotherapy, TKIs and ICIs
• Nanomedicine and materials for HCC or ICC treatment
• Molecular markers based on novel clinical laboratory technology
• HCC, ICC-related metabolic, metabolomics studies
• Progress in intrahepatic cholangiocarcinoma treatment and research
• Clinical application of surgical robots
• HCC, ICC-related organoid studies
Please note: manuscripts submitted consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: molecular targeted agents, nano-medicine, novel medical materials, new molecular markers, liver space-occupying lesions, chemotherapeutic agents, long-acting sustained-releasing formulation of anti-tumor agents
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
